Funder
Natural Science Foundation of Hunan Province
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference13 articles.
1. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol.,2012
2. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
3. Acquired resistance to crizotinib from a mutation in CD74-ROS1;Awad;N. Engl. J. Med.,2013
4. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer;Gainor;JCO Precis. Oncol.,2017
5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncol.,2017
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献